{"id":400882,"date":"2020-12-16T08:33:32","date_gmt":"2020-12-16T13:33:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400882"},"modified":"2020-12-16T08:33:32","modified_gmt":"2020-12-16T13:33:32","slug":"spero-therapeutics-added-to-the-nasdaq-biotechnology-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/","title":{"rendered":"Spero Therapeutics Added to the NASDAQ Biotechnology Index"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.<\/p>\n<p align=\"justify\">The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF (Nasdaq: IBB). More information about the NBI, including eligibility criteria, can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LJiaK1c6hka7EXthgWXg-gPbvmRvr10ovq3YzErhmqHMZrvUOZTqNFNGucmze3l_mfTWJkZ3112RfHwni3lNgXAvRwJc1sCJ8HNdTA5mQ49_evNWW4aCDrAjLtv1kC3YJBHxVa6eQN58ABe0qr-sknYaYZknnfdQhewOvyjVGA4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/indexes.nasdaqomx.com\/Index\/Overview\/NBI<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Spero\u00a0Therapeutics<\/strong><br \/>\n        <br \/>Spero Therapeutics, Inc.\u00a0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.<\/p>\n<p align=\"justify\">Spero\u2019s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In\u00a0September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. <br \/>\u00a0\u00a0 <br \/>Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. In December 2020, Spero announced the initiation of its Phase 2a clinical trial in patients with NTM pulmonary disease.<\/p>\n<p align=\"justify\">Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.<\/p>\n<p align=\"justify\">For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LJiaK1c6hka7EXthgWXg-kq0WBy-eSVngkY1BxmtV4KE8wLB4jzctpVKuFPKzzV_3dn6RIfJ_h-eNmJndCpTsBo-npp7d3xOCkVY7_Ff4FCirJ9OVW5SXgMmwCg_wMMMjuqJc4Bl8YdO1YPXbfDlCQBHyewfX3pD5OJUooRcjTl_uzN517b-egpzcBc8Ztrfd_jxYaDVDUi69MMIqIavivo-9KT5cD64mje9OSpN_ko6wEXFYF_FULEG5YoWe9XDPeu35HqAVsnJ_mgVkDDKZgugiVEvEVneuYXJKYu1FEg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/sperotherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Spero Investor and Media Contact:<\/strong><br \/>\n        <br \/>Sharon\u00a0Klahre<br \/>Vice President, Investor Relations<br \/>857-242-1547<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xtvYcyZpwmd-AQjL59AmGg5vykn6WyTtaJCujX5hCXchXAh4nDRkxlCx0dDPJc18S2XWqOTaS1IQ0PuzqTscnUsisQyNCl5lRh4NkqNfd3a92skqq_WuUKZOIghH_eWkiQp1EP-F3_Hfb-OpsRYskkEz-1tOW_XOmFpmYz0nlqlIT7xIV89X9c80mipQyPGi_0KmxUwiUz3aeJ9NuUoYHQ6gKeSTdR6Lx4URMxHCWGoMFWi5pMyvC2AH2935hTtFJY8DVpU8ezMrvbhUnllWhg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">IR@sperotherapeutics.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/2eb7fd6e-36ae-4389-8ddf-7463cb18dbe5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spero Therapeutics Added to the NASDAQ Biotechnology Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400882","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number &hellip; Continue reading &quot;Spero Therapeutics Added to the NASDAQ Biotechnology Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T13:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics Added to the NASDAQ Biotechnology Index\",\"datePublished\":\"2020-12-16T13:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"},\"wordCount\":334,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\",\"name\":\"Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\",\"datePublished\":\"2020-12-16T13:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics Added to the NASDAQ Biotechnology Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number &hellip; Continue reading \"Spero Therapeutics Added to the NASDAQ Biotechnology Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T13:33:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics Added to the NASDAQ Biotechnology Index","datePublished":"2020-12-16T13:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/"},"wordCount":334,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/","name":"Spero Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=","datePublished":"2020-12-16T13:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzI4NSMzODg0NDY5IzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-added-to-the-nasdaq-biotechnology-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics Added to the NASDAQ Biotechnology Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400882"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}